Concepts, Applications, and Requirements for Quantitative SPECT/CT

Eric C. Frey, Ph.D. (efrey@jhmi.edu) Division of Medical Imaging Physics Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University







Conflict of Interest Disclosure

Under a licensing agreement between the GE Healthcare and the Johns Hopkins University, Eric Frey is entitled to a share of royalty received by the University on sales of iterative reconstruction software used to obtain some results in this presentation.

Eric Frey is a co-founder of Radiopharmaceutical Imaging and Dosimetry, LLC. This company was founded to provide quantitative imaging and dosimetry service to developers of radiopharmaceutical therapy agents.

These interests have been disclosed and are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

Acknowledgements

• Funding: NIH Grants

- R01 EB 000288
- R01 CA 109234
- R01 EB 000168
- U01 CA 140204
- People
 - Bin He, Ph.D. (now at New York Hospital)
 - Yong Du, Ph.D.
 - Na Song, Ph.D. (Now at Montefiore Medical Center)
 - Lishui Cheng
 - Xing Rong
 - Nadège Anizan, Ph.D.
 - George Sgouros, Ph.D.

Outline

- Introduction to SPECT
- Applications of Quantitative SPECT
- Requirements for Quantitative SPECT
- Obstacles to Achieving Standardization



Two-Camera SPECT/CT Systems









Physical Image Degrading Factors

- Attenuation
- Scatter
- Collimator-Detector Response (CDR)
 - Geometric response
 - Septal penetration and scatter responses
- Partial Volume Effects
- Statistical Noise

Effects of high-energy emissions































Applications of Quantitative SPEC/CT

- Radiopharmaceutical Therapy Treatment Planning (absolute, lateral)
- Diagnosis (relative, lateral)
- Response to Therapy (relative, longitudinal)

Radiopharmaceutical Therapy (RPT)

- Agents (e.g., monoclonal antibodies, peptides, microspheres) that target tumors
- Bound to radionuclides whose emissions can kill tumor cells
 - Crossfire effect
 - Bystander effect
- Optimal dose is patient dependent
- Treatment planning to determine administered activity



Common Therapeutic Radionuclides for TRT

Radionuclide	Halflife (hr)	β- Energy (MeV)	γ Energy (keV) (% yield)
I-131	192.5	0.6 0	364 (82),
Y-90	64.0	2.28	none
Sm-153	46.3	0.81	103 (30),
Lu-177	161.5	0.50	208 (11),
Re-188	17.0	2.12	155 (15),















I-131 Physical Phantom

Philips Precedence SPECT/CT system with HEGP collimator



	Heart Chamber	Myocardium	Large Sphere	Small Sphere	Background
Volume (<i>ml</i>)	59.7	115.3	17.5 (r =1.61 cm)	5.7 (r =1.11 cm)	9580
Activity(<i>mCi</i>)	0.562	0.471	0.136	0.044	8.15
Activity concentration (<i>mCi/µl</i>)	9.38	4.08	7.77	7.72	0.851

128 projection views Acquisition time: 40s / view

	I-131	QSPI	ЕСТ		
Percent errors of a	ictivity estima <mark>Heart</mark>	tes for Anthro Large sp (r = 1.61 17.5 m	pomorphic† here Sn cm (r il)	torso phantom nall sphere = 1.11 cm 5.7 ml)	
AGS	-15.21	-26.12	2	-32.72	
ADS	4.75	-17.63		-25.77	
ADS+Dwn ⁺	-5.20	-21.10		-31.17	
ADS+Dwn+PVC*	-2.88	-15.49	9	-19.28	
50 iterations 24 subsets/iteration	AGS ⁺ DWN=model *PVC=recons	ADS -based downscatte truction-based PVC	ADS + Dwn r compensation C compensation	ADS+Dwn+PVE	

Y-90 QSPECT

• Physical phantom experiment

- Elliptical phantom with 3 spheres
- Philips Precedence SPECT/CT: HEGP
- Acquisition time per view: 45s/view
- Crystal thickness: 9.525 mm
- 128 projection views over 360°
- Matrix size per view: 128*128
- Pixel size: 4.664mm
- VOIs defined from CT



Y-90 Physical Phantom Study							
	5.5 cm diameter sphere	3.3 cm diameter sphere	1.5 cm diameter sphere				
% Error	-7.0%	-9.7%	-10.2%				
Error = (EstimatedActivity – TrueActivity) / TrueActivity × 100% ³⁹							



20





Accuracy of Activity Quantitation: I-123 Brain SPECT

RSD Striatal Phantom



Non-specific background uptake • GE Millennium VG/Hawkeye (5/8" thick crystal)

- LEHR Collimator
- 128 views/360°, 128*128 projection w/ 0.24 cm pixels
- CT attenuation maps
- Manually defined VOIs using registered MR Images
- Activity concentrations:
 - Bkg: 110 kBq/ml
 - Left Caudate: 212 kBq/ml
 - Left Putamen: 154 kBq/ml
 - Right Caudate: 1770 kBq/mI
 - Right Putamen: 222 kBq/ml

Y. Du, B.M.W. Tsui, and E.C. Frey, "Model-based compensation for quantitative I-123 brain SPECT imaging," *Phys Med Biol*, 51(5): 1269-1282, 2006



Requirements for Quantitative SPECT/CT

- Quality Control/Calibration
- Acquisition
- Reconstruction/Processing

Quality Control & Calibration

- Activity meter calibration and QC
- Routine Camera and CT QC
- Registration of SPECT and CT
- Calibration of QSPECT imaging

Calibration Factor Measurement

- Planar calibration (sensitivity)
 - Static image of standard source in air at known distance from camera
 - Sensitivity = std. counts/(std. activity * acq. time)
- Phantom-based Calibration
 - Acquire SPECT study of object with known activity
 - Reconstruct and compute counts
 - Scale factor is true phantom activity/image counts
 - Should be consistent with planar calibration for "ideal" reconstruction/compensation

Limitations of Planar Calibration Quantitative Y-90 SPECT

Planar Calibration

< <u>10 c</u>	an		Scanner	Calibration Factor
10-march			GE Discovery 670	1.14
SPECT Calibrat	tion		Siemens Symbia	1.08
Phantom	Dimensions] .		
Large Uniform	20 cm diameter		Scanner	Calibration Factor
Small Uniform 4.6 cm			GE Discovery 670	1.21-1.23
			Siemens	1.15-1.18
Sphere in cold	5.5 cm		Symbia	
	sphere in 32x20 phantom			



Suggests that consistent preparation and measurement of source activity is key

Acquisition Parameters

- Collimator selection
- Injected activity/acquisition time
- Voxel size
- Number of views
- Energy windows

Recon	struction/	Compen	sation
Factor	Large Object	Small Object	Commercially Available
Attenuation	Yes	Yes	Yes
Scatter	Yes	Yes	Energy-based: yes Model-based: limited
Geometric Response Compensation	No	Yes	Yes
Full CDR Compensation (High Energy)	Desirable for HE, ME radionuclides	Desirable for HE, ME radionuclides	No
Partial volume compensation	No	Yes	No
Noise Regularization	No	Yes?	Filtering

Obstacles to Standardization

- Radioactivity measurement
 - Variety of devices
 - Variety of radionuclides
- Compensation Methods
 - Many systems are SPECT-only
 - Variety of imaging hardware
 - Variety of image reconstruction and compensation methods
- Clinical Practice
 - Variation in protocols
 - Habits

Summary

- Quantitative SPECT/CT is achievable now
- There are a number of emerging clinical applications
- Limited commercial availability of state-ofthe-art reconstruction and compensation methods
- There is a need for standardization of protocols and methods